drugset / Trial / NCT06303583
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer
Timeline
- Start
- 2022-06-01
- Primary completion
- 2024-08-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Paclitaxel | Small molecule | 50 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |